Oxidative effect of several intravenous iron complexes in the rat

BioMetals

Volumn 26, Issue 3, 2013, Pages 473-478

  Bailie, George R ^a   Schuler, Catherine ^b   Leggett, Robert E ^b   Li, Hsin ^a   Li, Hsin Dat ^a   Patadia, Hiten ^a   Levin, Robert ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Intravenous iron; Iron dextran; Iron sucrose; Oxidative stress

Indexed keywords

2,4 DINITROPHENOL; 3 NITROTYROSINE; FERRIC CARBOXYMALTOSE; FERRINJECT; FERUMOXYTOL; IRON DEXTRAN; IRON SACCHARATE; LIQUID NITROGEN; UNCLASSIFIED DRUG; 3-NITROTYROSINE; FERRIC ION; FERRIC OXIDE, SACCHARATED; MAGNETITE; MALTOSE; NITROBENZENE DERIVATIVE; SACCHARIC ACID; TYROSINE;

ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART; IRON DEFICIENCY ANEMIA; KIDNEY; LIVER; LUNG; NONHUMAN; OXIDATIVE STRESS; RAT; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; DINITROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; GLUCARIC ACID; IRON-DEXTRAN COMPLEX; MALTOSE; OXIDATIVE STRESS; RATS; TISSUE DISTRIBUTION; TYROSINE;

EID: 84879199103     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-013-9632-4     Document Type: Article

References (32)

1. Anker SD, Comin Colet J, Filippatos G et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436-2448
2. Apopa PL, Qian Y, Shao R et al (2009) Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part Fibre Toxicol 6:1
3. Aronoff GR (2004) Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 15(Suppl 2):S99-S106
4. Bastit L, Vandebroek A, Altintas S et al (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611-1618
5. Bishu K, Agarwal R (2006) Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 1(Suppl 1):S19-S23
6. Dangsuwan P, Manchana T (2010) Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116:522-525
7. Danielson BG (2004) Structure, chemistry and pharmacokinetics of intravenous iron products. J Am Soc Nephrol 15:S93-S98
8. Evstatiev R, Marteau P, Iqbal T et al (2011) FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 141(846-853):e841-e842
9. Fishbane S (2003) Safety in iron management. Am J Kidney Dis 41:18-26
10. Geisser P, Baer M, Schaub E (1992) Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 42:1439-1452
11. Handelman GJ, Levin NW (2008) Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13:393-404
12. Hayat A (2008) Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 6:93-102
13. Johnson ACM, Becker K, Zager RA (2010) Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 299:F426-F435
14. Juan YS, Lin WY, Kalorin C, Kogan BA, Levin RM, Mannikarottu A (2007) The effect of partial bladder outlet obstruction on carbonyl and nitrotyrosine distribution in rabbit bladder. Urology 70:1249-1253
15. Khalafallah A, Dennis A (2012) Iron deficiency anemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy 2012:630519. doi: 10.1155/2012/630519 (Epub 2012 Jun 26)
16. Khalafallah A, Dennis A, Bates J et al (2010) A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 268:286-295
17. Krafft A, Breymann C (2011) Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study. J Obstet Gynaecol Res 37:119-124
18. Kuo KL, Hung SC, Wei YH, Tarng DC (2008) Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 19:1817-1826
19. Lin WY, Guven A, Juan YS et al (2008) Free radical damage as a biomarker of bladder dysfunction after partial outlet obstruction and reversal. BJU Int 101:621-626
20. Love AL, Billett HH (2008) Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol 83:403-409
21. Martin-Malo A, Merino A, Carracedo J et al (2012) Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transpl 27:2465-2471
22. Moore RA, Gaskell H, Rose P, Allan J (2011) Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord 11:4
23. Qunibi WY (2010) The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 60:399-412
24. Schiesser D, Binet I, Tsinalis D et al (2006) Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transpl 21:2841-2845
25. Stefansson BV, Haraldsson B, Nilsson U (2011) Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran. Nephron Clin Pract 118:c249-c256
26. Sturm B, Steinkellner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B (2010) In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress. Arzneimittelforschung 60:459-465
27. Sun CC, Vaja V, Babitt JL, Lin HY (2012) Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 87:392-400
28. Toblli JE, Cao G, Oliveri L, Angerosa M (2009a) Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforsch 59:176-190
29. Toblli JE, Cao G, Oliveri L, Angerosa M (2009b) Differences between the original iron sucrose complex Venofer and the iron sucrose similar Generis and potential implications. Port J Nephrol Hypertens 23:53-63
30. Toblli JE, Cao G, Olivieri L, Angerosa M (2010) Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transpl 25:3631-3640
31. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT (2009) Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 49:2719-2728
32. Zinderman CE, Landow L, Wise RP (2006) Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg 43:1004-1009